MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Cochlear launches iOS-connectable Nucleus 7 cochlear implant

Cochlear launches iOS-connectable Nucleus 7 cochlear implant

By

Cochlear Ltd.

Cochlear Ltd. (ASX:COH) today launched its Nucleus 7 sound processor cochlear implant, touting it as the smallest and lightest behind-the-ear implant sound processor available.

The Sydney-based company said that the newly launched Nucleus 7, which won FDA clearance last month, is the 1st cochlear implant designed to connect directly with Apple (NSDQ:AAPL) iOS devices, allowing individuals to stream sound from their compatible devices.

The Nucleus 7 will also allow users to control, monitor and customize their hearing on their attached smart device, the company said.

“The approval of the Nucleus 7 Sound Processor is a turning point for people with hearing loss, opening the door for them to make phone calls, listen to music in high-quality stereo sound, watch videos and have FaceTime calls streamed directly to their cochlear implant. This new sound processor builds on our long-standing commitment to help more people with hearing loss connect with others and live a full life,” CEO Chris Smith said in a prepared release.

The newly launched Nucleus 7 offers a hearing tracker feature which records coil-off time and time in speech, as well as an application to locate lost sound processors using location services. The system can also be used in combination with a hearing aid with synchronized streaming to both ears, the company said.

“Technology that offers greater connectivity seeks to make life easier for people with hearing loss. The advancements provided by the Nucleus 7 Sound Processor give parents more control and allow them to better monitor their child’s hearing while adults and teenagers will be able to stream music and make FaceTime calls just like their hearing friends and family,” Laurel Mahoney of the NYU Langone Medical Center said in a prepared statement.

The device is expected to be commercially available in September in the US and Canada, with options to upgrade to the device in October for individuals using the Nucleus CI24RE, CI500 and Profile Series implants, Cochlear said.

“The ability to control both hearing solutions through an iPhone or iPod touch and provide a seamless hearing experience between them is a remarkable technological step forward. At Cochlear, we design devices to give recipients greater flexibility to personalize their settings and manage their hearing loss on a daily basis, and these new solutions offer that experience like never before,” R&D senior VP Jan Janssen said in a press release.

In case you missed it

RSS From Medical Design & Outsourcing

  • These medtech companies care a lot about research
    They’re making glaucoma-treating stents, tumor-treating fields, coin-sized CGMs and more. Discover the medtech companies that spend the most on research as a percentage of revenue. The list comes from our annual Big 100 report, which examines the world’s 100 largest medical device companies and ranks them by revenue. (Check out our full Big 100 report… […]
  • Traco Power launches new AC/DC power supplies
    Traco Power (Baar, Switzerland) announced its newest high efficiency, miniaturized ac/dc power supplies: the TPP 180 series for medical and industrial and TPI 180 for industrial. The power supplies measure only 2-by-3-by-1.24 inches in the open frame version — with global safety approvals for medical or industrial markets. They come in16 standard models with single… […]
  • NIH launches $9.8M neuromodulation competition
    The National Institutes of Health (NIH) announced today that it launched the first phase of its Neuromod Prize competition. Neuromod Prize, a $9.8 million competition, aims to accelerate the development of neuromodulation therapies. NIH seeks scientists, engineers and clinicians to submit novel concepts and clinical development plans to demonstrate solutions for stimulating the peripheral nervous… […]
  • Junkosha boosts production of PTFE liners and FEP-based heat shrink
    Junkosha announced today that it plans to double production capacity to meet shortages of PTFE liners and FEP-based heat shrink for catheter manufacturers. Both OEMs and contract manufacturers in the catheter space are stressed from shortages in the global supply of vital components, according to the Japanese maker of sophisticated fluoropolymer application technologies. “We believe this… […]
  • Ahead of G7 launch, Dexcom CEO plans for ‘more activity than we’ve ever seen’ in 2022
    With a major product approval and launch in its sights, Dexcom prepares for a big year in 2022. Across 2021, Dexcom (NSDQ:DXCM) took several steps forward. The company touted its next-generation G7 continuous glucose monitor (CGM) and announced a major regulatory nod and partnership for real-time application programming interfaces (APIs), to list a couple. As the new year gets underway, expectations for the… […]
  • Former Zimmer Biomet executive has a new job
    Carrie Nichol, the former chief accounting officer of Zimmer Biomet (NYSE:ZBH), has a new job outside of the medtech industry. Nichol, who also served as vice president, controller and principal accounting officer at Zimmer Biomet, is now a VP and controller at Minnetonka, Minnesota-based Cargill. Her departure was among the many notable medtech executive moves… […]
  • Employees say Intuitive, Boston Scientific, J&J, Medtronic are among the best places to work in 2022
    Intuitive Surgical, Boston Scientific, Johnson & Johnson and Medtronic were recently named by Glassdoor as Best Places to Work in 2022 based on employee reviews. Each year, Glassdoor uses feedback that employees have shared on the website over the past 12 months to compile a list of the best places to work for the upcoming… […]
  • Medtronic’s M&A strategy explained by CFO Karen Parkhill
    When Medtronic CFO and EVP Karen Parkhill looks back at the medical device manufacturer’s performance through the COVID-19 pandemic, she recalls a key decision that rankled investors but paid off in the long run. “When I first joined Medtronic, it was shortly after the Covidien merger and we had taken on a lot of debt… […]
  • Loftware acquires Prisym ID
    Loftware announced that it acquired Prisym ID, a provider of regulated content and label management solutions. Prisym ID focuses on clinical trials, medical device and pharmaceutical labeling, with the acquisition set to expand Loftware’s enterprise labeling solution offerings for the medical device and pharmaceutical industries while enhancing Loftware’s end-to-end, cloud-based labeling platform with advanced clinical… […]
  • BD, Pfizer, Wellcome want to improve hospitals’ antimicrobial practices
    BD (NYSE:BDX) announced yesterday that it will collaborate with Pfizer (NYSE:PFE) and Wellcome to advance antimicrobial stewardship practices. The collaboration builds on ongoing efforts to advance the role of diagnostics in addressing the challenge of antimicrobial resistance (AMR), according to a news release. The companies will survey existing diagnostic practices to highlight benefits and gaps… […]
  • iRhythm CEO considers costs on the path to profitability
    Fresh off positive reimbursement news for its Zio remote external electrocardiogram monitoring device, the CEO of iRhythm Technologies (NSDQ:IRTC) doesn’t just have revenue on his mind. iRhythm President and CEO Quentin Blackford — the former Dexcom COO who replaced Mike Coyle in September — said his company will need to keep costs under control as it… […]